The user is seeking alternative hair loss treatments due to side effects from finasteride and minoxidil. They are inquiring about the availability of gt20029 from u-lab.
HairClone plans to start hair multiplication services in 2022. Users discuss various treatments like Minoxidil, finasteride, PRP, and hair cloning, expressing both hope and skepticism about the technology and its costs.
The conversation discusses hair regrowth treatments, including stemcell exosomes, PRP, and PP405. Users question the effectiveness of the treatments and mention finasteride and minoxidil.
The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.
HairClone is offering a Dermal Papilla Cell Hair Multiplication procedure in Guatemala, raising questions about its effectiveness and regulatory reasons for the location. Users express skepticism and curiosity about the treatment's success and potential costs.
A Swiss product called Redensyl, which is supposed to target hair follicle stem cells and has recently been marketed in Europe. The post inquires if anyone has had any experience with the product.
Regenera Activa and exosome therapy are discussed for hair loss treatment, focusing on their effectiveness for regrowth, thickening, or reducing shedding. Users are seeking experiences and results from these treatments.
A human trial involving the use of Verteporfin as a treatment for hair loss, which has been ongoing for 119 days with an update on its progress. Treatments such as Minoxidil, Finasteride and RU58841 have also been discussed.
Hair loss treatments include finasteride, minoxidil, microneedling, dutasteride, CB-03-01, RU-58841, and experimental options like KY-19382 and stemcell therapy. Some treatments are considered ineffective or risky, such as ketoconazole, PRP, and low-level laser therapy.
Oleic acid and microneedling are being explored for hair regrowth, but results are mixed. Addressing DHT and fibrosis is crucial, with treatments like finasteride, minoxidil, and scalp massage also discussed.
Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.
MCL-1 protein may help maintain hair follicles in the growth phase and prevent miniaturization. There is interest in experimental treatments like exosomes, peptides, or stemcell serums to upregulate MCL-1 for hair loss, especially for those not using minoxidil or finasteride.
The user shared their positive experience with a hair transplant in South Korea, highlighting thorough consultations, consistent medical team involvement, and reasonable pricing. They noted good growth and natural-looking results after several months, with stemcell PRP treatment included to support graft survival.
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.
The conversation is about finding high-purity RU58841 solutions for hair loss treatment, with mentions of Anagenic, Selleckchem, MV Supplement, and rudirect.co.uk as potential sources. Users discuss their experiences and preferences regarding product quality and shipping.
The conversation is about making RU58841 solutions for hair loss treatment and sourcing ingredients for KB solutions. The user mentions using RU58841 powder from Shaanxi Greenyobiotech.
OrganTech is working on regenerating hair and teeth, with positive results in mice, but skepticism remains about progress for humans. Users express frustration over the lack of advancements in human hair loss treatments, despite ongoing research and trials.
New hair loss treatments like PP-405, AMP-303, and SCUBE3 are being discussed, but none are confirmed to fully restore hairlines. Current treatments like Minoxidil, Finasteride, and RU58841 are still widely used, with some hope for future advancements in hair regrowth.
PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.
A group buy for hair loss treatments including Harmine 19a, TM5614, Abiraterone Acetate, and others. A compound, BMS-202, that can potentially reverse gray hair is also mentioned.
A user shared their positive experience with PRP and stemcell treatment for hair loss, noting it nearly stopped their hair loss after previous use of finasteride and minoxidil. Another user mentioned PRP helped maintain their hair, though its effectiveness decreased over time, and they experienced side effects from dutasteride.
A new "third cell" discovery in Japan could be key to fully regenerating hair follicles, with human trials possibly starting in 2027-2028. AI is expected to accelerate medical discoveries, potentially leading to a hair loss cure within a few years.
Verteporfin reduces scar tissue in hair transplants but doesn't significantly regrow hair follicles. More testing is needed to determine its effectiveness.
The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.
Verteporfin is being explored for its potential to improve hair transplant outcomes by reducing scarring and increasing donor hair follicles. There is skepticism about the results, with some claiming misleading presentation of evidence.
The conversation discusses a patent filed by Shiseido for cloning Dermal Papilla (DP) cells to treat hair loss. The method involves using viral vectors to maintain the cells' growth-inducing properties, differing from Replicel's approach with Dermal Sheath Cup (DSC) cells.
Low-Level Laser Therapy (LLLT) is considered expensive and may not provide significant benefits, with some users suggesting alternatives like finasteride, minoxidil, and microneedling. Many users report limited success with LLLT and similar treatments, recommending more proven options instead.
Hair loss treatments like GT20029, pyrilutamide, and Follica show promise in 2022. Phase 1 and 2 trials are underway, and new hair growth studies have been published.
A user trying to avoid an expensive hair transplant, and the replies suggesting they wait two years on treatment before deciding if they need a transplant or not.